Issue 078

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last Friday I wrote about ICER's blistering report on Pear, Orexo's DTC move with its substance use disorder DTx, plus feedback for CMS on its plans for reimbursing breakthrough devices.

And if you

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!
×

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases

Research Reports

All Research Reports
The Virgin Pulse Report
9.25.20
14 min. read
The Evidation Health Report
8.21.20
14 min. read
The Proteus Digital Health Report
6.20.20
17 min. read
The Hinge Health Report
4.24.20
17 min. read

Newsletters

All Newsletters
Secret Peloton acquisition. $575M in funding.
11.16.20
9 min. read
Scoop: Amwell in talks to buy Omada
11.13.20
6 min. read
Details on Virta Health’s VA deal
11.11.20
10 min. read
Pre-Post: Cohero. $260M across 20 deals.
11.09.20
6 min. read

Databases

All Databases
Prescription Digital Therapeutics Pipeline of Pipelines
11.02.20
1 min. read
Database: Digital health companies with approved PPP loans
7.09.20
1 min. read